Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 02 02 2021
accepted: 01 03 2021
entrez: 5 4 2021
pubmed: 6 4 2021
medline: 25 2 2023
Statut: epublish

Résumé

To investigate the activation of the IFNγ signaling pathway in monocytes of patients with secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS) and to evaluate whether levels of phosphorylated STAT1 represent a biomarker for the identification of patients at early stages of the disease. Fresh whole blood samples from pediatric patients with active sHLH/MAS, not receiving (n=10) and receiving glucocorticoids (n=14) at time of sampling, were prospectively collected. As disease control groups, patients with active systemic juvenile idiopathic arthritis (sJIA) without MAS, patients with sHLH/MAS in remission and patients with other rheumatic diseases were also sampled. Whole blood cells were left unstimulated or stimulated with increasing concentrations of IFNγ for 10 minutes and the intracellular Tyrosine (701)-phosphorylated STAT1 (pSTAT1) levels were evaluated in monocytes by flow cytometry. Monocytes from untreated sHLH/MAS patients showed significantly higher basal levels of pSTAT1 compared to those observed in monocytes from glucocorticoid-treated sHLH/MAS patients and from all the other disease controls. In addition, a significant increase in responsiveness to IFNγ, as assessed by increased levels of pSTAT1 following Our data demonstrating higher basal levels of pSTAT1 as well as a hyperreactivity to IFNγ stimulation in monocytes from patients with sHLH/MAS point to perturbations in the activation of downstream IFNγ signaling pathway as a contributor to the hyperinflammation occurring in these patients. Finally, the observation that glucocorticoids affect pSTAT1 levels

Identifiants

pubmed: 33815425
doi: 10.3389/fimmu.2021.663329
pmc: PMC8010171
doi:

Substances chimiques

Biomarkers 0
STAT1 Transcription Factor 0
STAT1 protein, human 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

663329

Informations de copyright

Copyright © 2021 Pascarella, Bracaglia, Caiello, Arduini, Moneta, Rossi, Matteo, Pardeo, De Benedetti and Prencipe.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Ann Rheum Dis. 2020 Dec 4;:
pubmed: 33277241
PLoS One. 2019 Dec 17;14(12):e0226043
pubmed: 31846457
Adv Immunol. 2007;96:41-101
pubmed: 17981204
J Exp Med. 2011 Jun 6;208(6):1203-14
pubmed: 21624938
Cytokine. 2010 Apr;50(1):1-14
pubmed: 20036577
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Arthritis Rheumatol. 2019 Nov;71(11):1943-1954
pubmed: 31379071
J Clin Invest. 2011 Jun;121(6):2264-77
pubmed: 21576823
Nat Immunol. 2008 Apr;9(4):378-87
pubmed: 18345002
J Allergy Clin Immunol Pract. 2019 Mar;7(3):824-832
pubmed: 30557712
Blood. 2004 Aug 1;104(3):735-43
pubmed: 15069016
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
N Engl J Med. 2020 May 7;382(19):1811-1822
pubmed: 32374962
Clin Immunol. 2019 Nov;208:108252
pubmed: 31449879
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101515
pubmed: 32387063
Ann Rheum Dis. 2017 Jan;76(1):166-172
pubmed: 27296321
J Rheumatol. 2004 Nov;31(11):2290-4
pubmed: 15517647
Arthritis Rheum. 2012 Nov;64(11):3799-808
pubmed: 22740319
J Clin Immunol. 2020 Jul;40(5):699-707
pubmed: 32447592
J Allergy Clin Immunol. 2018 Apr;141(4):1439-1449
pubmed: 28807602
J Immunol. 2003 May 1;170(9):4833-9
pubmed: 12707366
J Leukoc Biol. 2004 Feb;75(2):163-89
pubmed: 14525967
Ann Rheum Dis. 2016 Mar;75(3):481-9
pubmed: 26865703
Ann Transl Med. 2020 Jul;8(14):887
pubmed: 32793731
Nat Immunol. 2002 Sep;3(9):859-66
pubmed: 12172544

Auteurs

Antonia Pascarella (A)

Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Claudia Bracaglia (C)

Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Ivan Caiello (I)

Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Alessia Arduini (A)

Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Gian Marco Moneta (GM)

Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Marianna Nicoletta Rossi (MN)

Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Valentina Matteo (V)

Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Manuela Pardeo (M)

Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Fabrizio De Benedetti (F)

Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Giusi Prencipe (G)

Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH